Abstract
Over the last century, the prevalence of type 2 diabetes has dramatically increased, reaching the status of epidemic. Because insulin resistance is considered the primary cause of type 2 diabetes, the identification of the cellular processes and gene networks that lead to an impairment of insulin action in target tissues is of crucial importance for the development of new drugs and therapeutic strategies to treat or prevent the disease. Numerous studies in humans and animal models have shown that insulin resistance is frequently associated to reduced mitochondrial mass or oxidative function in insulin sensitive tissues, leading to the hypothesis that defective overall mitochondrial activity could play a relevant role in the etiology of insulin resistance and, therefore, in type 2 diabetes. Although the causal relationship between mitochondrial dysfunction and insulin resistance is still controversial, numerous studies show that lifestyle or pharmacological interventions that improve insulin sensitivity are frequently associated to an increase in mitochondrial function and whole body energy expenditure. Therefore, increasing mitochondrial mass and oxidative activity is viewed as a potential therapeutic approach for the treatment of insulin resistance. Here, we review the current knowledge on the role of mitochondria in the pathogenesis of insulin resistance and discuss some of the potential therapeutic strategies and pharmacological targets for the treatment of insulin resistance based on the activation of mitochondrial biogenesis and the increase of mitochondrial oxidative function.
Keywords: Type 2 diabetes, mitochondrial dysfunction, calorie restriction, exercise, AMPK, SIRT1, PGC-1.
Current Pharmaceutical Design
Title:Targeting Mitochondrial Biogenesis to Treat Insulin Resistance
Volume: 20 Issue: 35
Author(s): Monica Zamora and Josep A. Villena
Affiliation:
Keywords: Type 2 diabetes, mitochondrial dysfunction, calorie restriction, exercise, AMPK, SIRT1, PGC-1.
Abstract: Over the last century, the prevalence of type 2 diabetes has dramatically increased, reaching the status of epidemic. Because insulin resistance is considered the primary cause of type 2 diabetes, the identification of the cellular processes and gene networks that lead to an impairment of insulin action in target tissues is of crucial importance for the development of new drugs and therapeutic strategies to treat or prevent the disease. Numerous studies in humans and animal models have shown that insulin resistance is frequently associated to reduced mitochondrial mass or oxidative function in insulin sensitive tissues, leading to the hypothesis that defective overall mitochondrial activity could play a relevant role in the etiology of insulin resistance and, therefore, in type 2 diabetes. Although the causal relationship between mitochondrial dysfunction and insulin resistance is still controversial, numerous studies show that lifestyle or pharmacological interventions that improve insulin sensitivity are frequently associated to an increase in mitochondrial function and whole body energy expenditure. Therefore, increasing mitochondrial mass and oxidative activity is viewed as a potential therapeutic approach for the treatment of insulin resistance. Here, we review the current knowledge on the role of mitochondria in the pathogenesis of insulin resistance and discuss some of the potential therapeutic strategies and pharmacological targets for the treatment of insulin resistance based on the activation of mitochondrial biogenesis and the increase of mitochondrial oxidative function.
Export Options
About this article
Cite this article as:
Zamora Monica and Villena A. Josep, Targeting Mitochondrial Biogenesis to Treat Insulin Resistance, Current Pharmaceutical Design 2014; 20 (35) . https://dx.doi.org/10.2174/1381612820666140306102514
DOI https://dx.doi.org/10.2174/1381612820666140306102514 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Selective Inhibitors of Zinc-Dependent Histone Deacetylases. Therapeutic Targets Relevant to Cancer
Current Pharmaceutical Design Recommendations for the Treatment of Hypertension in Elderly People
Cardiovascular & Hematological Agents in Medicinal Chemistry The Possible Role of Saponin in Type-II Diabetes- A Review
Current Diabetes Reviews The Impact of Type 2 Diabetes on Women’s Health and Well-being During Their Reproductive Years: A Mixed-methods Systematic Review
Current Diabetes Reviews Endothelial Function Assessment in Complicated Hypertension
Current Pharmaceutical Design Protein Glycation: An Old Villain is Shedding Secrets
Combinatorial Chemistry & High Throughput Screening Angiotensin Converting Enzyme 2 Activator (DIZE) Modulates Metabolic Profiles in Mice, Decreasing Lipogenesis
Protein & Peptide Letters Genetic Studies of Type 2 Diabetes in South Asians: A Systematic Overview
Current Diabetes Reviews Genomics and the Prospects of Existing and Emerging Therapeutics for Cardiovascular Diseases
Current Pharmaceutical Design The Role of Statins in Preventing the Progression of Congestive Heart Failure in Patients with Metabolic Syndrome
Current Pharmaceutical Design Blockade of the Renin-Angiotensin-Aldosterone System: Effects on Hypertensive Target Organ Damage
Cardiovascular & Hematological Agents in Medicinal Chemistry Vitamin D in Acute Kidney Injury
Inflammation & Allergy - Drug Targets (Discontinued) Cardiovascular Disease in Patients with Diabetic Nephropathy
Current Molecular Medicine Impact of Sitagliptin on Non-diabetic Covid-19 Patients
Current Molecular Pharmacology Chymase as an Important Target for Preventing Complications of Metabolic Syndrome
Current Medicinal Chemistry Therapeutic Angiogenesis by Gene Therapy for Critical Limb Ischemia: Choice of Biological Agent
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Advances in Drug Safety
Current Pharmaceutical Design Synthesis, Antidiabetic and Hypolipidemic Activities of New Diethylamine and Triethoxysilyl Derivatives of Tolbutamide on Rats
Medicinal Chemistry Dicarbonyls Generation, Toxicities, Detoxifications and Potential Roles in Diabetes Complications
Current Protein & Peptide Science Relaxin, Insulin and Diabetes: An Intriguing Connection
Current Diabetes Reviews